A recent study has shown that pTERT mutations are associated with SEL1L overexpression in glioblastoma; high SEL1L immunoreactivity correlates with tumour progression, cell proliferation, decreased OS and poorer response to therapy (Mellai et al. 2020). The gene discussed is SEL1L; the disease is glioblastoma.